Soleno Therapeutics (SLNO) Profit After Tax (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Profit After Tax data on file, last reported at $31.4 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 171.68% year-over-year to $31.4 million in Q1 2026; TTM through Mar 2026 was $96.1 million, a 148.57% increase from a year earlier, with the FY2025 full-year figure at $20.9 million, up 111.93% from the prior year.
• Profit After Tax for Q1 2026 stood at $31.4 million, down from $43.4 million in the prior quarter.
• Over the last five years, Profit After Tax for SLNO reached as high as $43.4 million in Q4 2025 and fell as low as -$76.6 million in Q3 2024.
• Historically, Profit After Tax has averaged -$11.0 million across 5 years, with a median of -$8.4 million in 2023.
• Across the five-year window, Profit After Tax slumped 605.36% in 2024 and jumped 178.05% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$5.5 million in 2022, then slumped by 105.91% to -$11.3 million in 2023, then sank by 392.4% to -$55.6 million in 2024, then soared by 178.05% to $43.4 million in 2025, then declined by 27.72% to $31.4 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were $31.4 million in Q1 2026, $43.4 million in Q4 2025, and $26.0 million in Q3 2025.